Vergidis, Paschalis
Denning, David W.
Article History
First Online: 30 January 2020
Compliance with ethics guidelines
:
: Dr. Vergidis reports that he has received honoraria from Pfizer.Dr. Denning reports that he and his family hold Founder shares in F2G Ltd., a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Cidara, Pulmatrix, Zambon, iCo Therapeutics, Roivant, and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan, and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group, and the British Society for Medical Mycology Standards of Care committee.
: This article does not contain any studies with animal subjects performed by any of the authors. David Denning has contributed to a clinical trial (ref 48).